Digital Duet 2.0 with Dr. Jai

After years of treating glaucoma patients, I’ve seen the field move toward interventional glaucoma—an approach that relies on lasers, drug delivery, and minimally invasive glaucoma surgery (MIGS), and reduces the long-term burden of topical eye drops. In our office and practice, SLT has become a cornerstone of that shift. I’ve seen firsthand how taking a proactive, rather than a reactive, approach to managing glaucoma can improve clinical outcomes, ensure better compliance, and simplify patient care.

Because SLT plays such a central role in how I treat glaucoma, the laser I use matters—and Digital Duet 2.0 sets the new gold standard in SLT+YAG technology for glaucoma and posterior capsulotomy treatment. This next-generation platform from Lumenis, the inventor of SLT, combines imaging and connectivity with a user-centric experience that transforms how ophthalmologists operate. It checks all the boxes: safety, efficacy, efficiency, and ease of use.

What’s New with Digital Duet 2.0

For me, the upgrade to Digital Duet 2.0 feels like going from an older iPhone straight to an “iPhone 20,” which has yet to even exist. It’s that kind of leap where everything is faster, sharper, and far more intuitive the moment you start using it.

Digital Duet 2.0’s tailored design brings advanced high-resolution imaging to the center of ophthalmic care. Its enhanced integrated camera enables live viewing, high-quality image capture, and video recording, supporting diagnosis, documentation, and communication. I can capture angle imagery, monitor disease progression, and even use these recordings as a teaching tool for my staff or to help patients better understand their condition. It also includes adjustable imaging brightness and optimized visualization, further improving precision.

Digital Duet 2.0 combines these advanced digital capabilities with Lumenis’s best-in-class SLT+YAG laser technology. The system features the premium optics of Lumenis engineering, a super-Gaussian beam profile, and SmartV titratable on-axis/off-axis illumination, all of which contribute to optimal visualization and energy efficiency.

Beyond its glaucoma applications, Digital Duet 2.0 also elevates YAG capsulotomy. As more post-cataract surgery patients expect to avoid glasses, even a thin layer of posterior capsule opacification can affect their vision. With this platform, clearing that Saran Wrap-like tissue takes only seconds. The enhanced interface and precision optics make the procedure smoother for surgeons and more comfortable for patients.

Workflow benefits

The platform brings meaningful upgrades to clinical workflow. Digital Duet 2.0 integrates network-ready connectivity and automated reporting, connecting directly with EMR/EHR systems to simplify documentation and ensure secure data exchange. Customizable clinical reports are generated automatically to reduce administrative burden for my staff, and the full HD 15.6-inch touchscreen and heads-up display integrate imaging, data, and laser controls into a single, intuitive workspace. With optimized anterior and posterior offset, the system provides more flexibility and offers a premium experience that complements high-performing ophthalmic practices like mine.

Ultimately, these workflow improvements give us greater flexibility. In a busy clinic, every minute counts, and the design of Digital Duet 2.0 allows me to move easily between rooms, add patients when needed, and work through a full SLT morning or afternoon without feeling rushed. My scribe can say, “Go to room five,” and I can step in to perform an SLT without disrupting the schedule. When a system can be operated instantly and stays ready throughout the day, we can treat more patients while maintaining a steady, safe pace of care.

Backed by the LiGHT trial

As we look at what Digital Duet 2.0 brings to SLT, it’s important to consider the strength of the evidence behind this procedure. The multicenter, randomized LiGHT trial compared SLT with topical medications and followed patients for six years, showing that SLT performed exceptionally well as a first-line treatment. A more recent detailed analysis of the data demonstrated that visual field progression was 29% slower in the SLT-first group compared with the drops-first group, confirming earlier findings.

The LiGHT trial consistently showed that SLT did a terrific job caring for these patients. For me, it reinforces what we see in practice every day: SLT helps reduce polypharmacy, improves compliance, and gives patients a healthier ocular surface. It’s why so many of us have shifted to using lasers earlier—often first line, or as a replacement for one or even two drops in patients who have struggled with long-term medication use. That’s why the technology delivering SLT matters, and Digital Duet 2.0’s next-generation platform directly supports the level of care the LiGHT trial helped establish.

Why it Matters

You can’t prevent glaucoma, but you can prevent progression—and the one thing we can control right now is pressure. Digital Duet 2.0 gives us a safe way to treat earlier, reduce drop dependence, and preserve the ocular surface.

Nobody wants to lose their sight, and nobody wants a lifetime of medication burden. That’s why having the right platform matters. Digital Duet 2.0 brings together proven

laser technology with a doctor-focused design to support where interventional glaucoma is headed—leading to a better experience for both patients and practices. When the laser we use is fast, consistent, and built for how we actually work, it strengthens everything we’re trying to accomplish: safer care, better outcomes, and the ability to meet patients where they are.